Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T00:21:54.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A sitewide NIH announcement about terminology changes appears above the study record error page. The site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:24:44.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The site's footer revision label changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:31:17.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page with a 403 header and a Home button, indicating restricted access to the study record rather than an ordinary content update.
    Difference
    21%
    Check dated 2026-09-23T00:24:21.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page footer now displays the site revision as v3.7.0, replacing the previous v3.6.6, reflecting a software revision update.
    Difference
    0.0%
    Check dated 2026-09-15T23:28:32.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6. This indicates a minor update to the page version and routine maintenance rather than any visible content change.
    Difference
    0.0%
    Check dated 2026-09-01T18:07:01.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.